Clinical Trial Update: Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

View source ↗

Summary

This clinical trial registry entry notes that the study evaluating the optimal duration of neoadjuvant therapy for resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Kochi University | Conditions: Pancreatic Cancer Resectable | Status: COMPLETED